论文部分内容阅读
目的研究PPARγ激动剂山奈酚对糖尿病大鼠视网膜病变的作用机制。方法高糖高脂饲料喂养加腹腔注射链脲佐菌素建立2型糖尿病大鼠模型,实验组灌胃给予山奈酚50 mg/(kg·d)、100 mg/(kg·d)、200 mg/(kg·d),灌胃给药10周后,酶联免疫吸附法测定各组大鼠血清中IGF-1、E-selectin和VEGF含量,real-time PCR法测定视网膜组织中IGF-1和VEGF的mRNA表达,免疫组化法检测视网膜组织中MMP-2表达。结果与糖尿病模型组大鼠相比,山奈酚治疗组IGF-1表达呈上升趋势,VEGF、E-selectin和MMP-2表达有所降低,且存在显著性差异。结论山奈酚可通过上调IGF-1表达、下调VEGF、E-selectin和MMP-2表达,发挥对糖尿病视网膜微血管病变的保护作用。
Objective To study the mechanism of action of kaempferol, a PPARγ agonist, on retinopathy in diabetic rats. Methods The model rats with type 2 diabetes were established by intraperitoneal injection of streptozotocin (STZ). The rats in the experimental group were given kaempferol 50 mg / (kg · d), 100 mg / (kg · d), 200 mg / (kg · d). After 10 weeks of intragastric administration, the levels of IGF-1, E-selectin and VEGF in serum of rats in each group were measured by enzyme linked immunosorbent assay. IGF-1 And VEGF mRNA expression, retinal tissue MMP-2 expression by immunohistochemistry. Results Compared with the diabetic model group, the expression of IGF-1 in kaempferol treatment group was up-regulated, the expression of VEGF, E-selectin and MMP-2 were decreased, and there was a significant difference. Conclusion Kaempferol can protect the diabetic retinopathy by up-regulating the expression of IGF-1, down-regulating the expression of VEGF, E-selectin and MMP-2.